secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001213900-22-007911
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx preliminary Q4 revenue ~$20.3M record; guides 2022 revenue $80-85M
-----------------------------------------------------------------------------

- Preliminary Q4 2021 revenue ~$20.3M (record); full-year revenue rose 42% YoY.
- GAAP net income $0.6M; record quarterly adjusted EBITDA $4.0M.
- 2022 guidance: revenue $80-85M (31-39% growth); gross margins 57-60%.
- New KPIs: avg revenue per top-20 pharma manufacturer $2.5M; net revenue retention 127%; revenue per FTE $730K.
- Top 20 pharma customer penetration increased to 95% from 85% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022007911/0001213900-22-007911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022007911/ea155745-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-007911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer